All In Biotech

Drug Trial Radar · NCT05807399

PanACEA - STEP2C -01

A Multiple-arm, Multiple-stage (MAMS), Phase 2B/C, Open-label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including Optimised Use of Existing and Introduction of Novel Anti-tuberculosis Drugs, in Adults With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis

Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Apr 14, 2023

Primary completion

Oct 31, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Michael HoelscherAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Radboud University Medical Center; University of California, San Francisco; University College, London; GlaxoSmithKline; LigaChem Biosciences, Inc.
First posted
Apr 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2B/C, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis. In stage 1, participants will be randomly allocated to the control or one of the 2 rifampicin-containing experimental regimens in the ratio 1:1:1. In stage 2, the experimental arm 4 containing BTZ-043 will be added. The allocation ratio will be changed to co-enrol the remaining participants in arms 1- 3 simultaneously with arm 4 in a ratio of 1:1:1:2. When arms 1-2 are fully enrolled and arm 4 is not, further participants will be randomized 1:1 to control and experimental arm 4. Not all countries will participate in stage 2. In stage 3, participants will be allocated in parallel to control arm treatment (now designated arm 7) or the experimental arms 5 and 6, favouring arm 5, 2:1:1 over arms 6 and control. This stage will start after completion of recruitment in the stages 1 and 2. Enrolment of participants into arm 5 will proceed following review of data from the ENABLE/UNITE-03 (NCT06748937), non-clinical safety data and after endorsement by the DSMB. Thus, arm 5 recruitment might start after arms 6 and 7, which may require an increase in the control arm sample size to ensure controls are recruited concomitantly.

Conditions

  • Pulmonary Tuberculosis
  • Other Specified Pulmonary Tuberculosis

Interventions

  • BTZ-043Drug

    BTZ-043 1000mg once daily in arms 4 and 6.

  • RifampicinDrug

    Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3, 5 and 7.

  • IsoniazidDrug

    Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3 and 7.

  • PyrazinamideDrug

    Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3, 5 and 7.

  • MoxifloxacinDrug

    Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2.

  • Alpibectir (GSK3729098)Drug

    Alpibectir 45 mg OD plus Ethionamide 500 mg OD combined with rifampicin pyrazinamide and ethambutol at standard weight-banded doses in arm 5.

  • Ganfeborole (GSK3036656)Drug

    Ganfeborole 20 mg OD in arm 6

  • Delpazolid (LCB01-0371)Drug

    Delpazolid 1200mg OD in arm 6

  • Pretomanid (Pa)Drug

    Pretomanid 20mg OD in arm 6.

  • Ethambutol (E)Drug

    Ethambutol 20mg/Kg OD in arm 3, 5 and 7

  • EthionamideDrug

    Ethionamide 500mg OD in arm 5.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to stable culture conversion to negative in liquid mediaTime frame: Day 01- Week 26
  2. Change in Mycobacterial load (Stage 3)Time frame: Baseline until week 12 of treatment.

Locations

10 sites in 6 countries. Site status is shown where the registry gives one.

  • Centre de Recherches Médicales de Lambaréné (CERMEL)

    Lambaréné, Gabon · Completed

  • Kamuzu College of Health Sciences (formerly College of Medicine)

    Blantyre, Malawi · Recruiting

  • Instituto Nacional de Saúde (INS)

    Maputo, Mozambique · Recruiting

  • TASK Applied Sciences Clinical Research Centre

    Cape Town, South Africa · Recruiting

  • University of Cape Town Lung Institute

    Cape Town, South Africa · Not yet recruiting

  • Isango Lethemba TB Research Unit. Clinical HIV Research Unit (CHRU), Wits Health Consortium.

    Port Elizabeth, Eastern Cape, South Africa · Not yet recruiting

  • Ifakara Health Institute (IHI)

    Bagamoyo, Tanzania · Recruiting

  • Kilimanjaro Clinical Research Institute (KCRI)

    Moshi, Tanzania · Recruiting

  • National Institute for Medical Research (NIMR-MMRC)

    Mbeya, Mbeya, Tanzania · Recruiting

  • Makerere University Lung Institute Limited

    Kampala, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.